Biocompatible peritoneal dialysis solutions: Do they indeed affect the outcome?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 4, 2009, Pages 242-247

  Grzegorzewska, Alicja E ^a,b  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Transplantology i Chorób Wewnetrznych   (Poland)

Author keywords

Amino acids; Bicarbonate; Biocompatibility; Dialysis solutions; Glucose polymers

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE DEGRADATION PRODUCT; GLUCOSE POLYMER; INTERLEUKIN 6; PERITONEAL DIALYSIS FLUID; UREA;

ACID BASE BALANCE; ADVERSE OUTCOME; BIOCOMPATIBILITY; CLINICAL TRIAL; HUMAN; KIDNEY FUNCTION; MALNUTRITION; MESOTHELIUM CELL; MORTALITY; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PH MEASUREMENT; REVIEW; SURVIVAL RATE; ULTRAFILTRATION;

EID: 67149094950     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.666     Document Type: Review

References (49)

1. Posthuma N, ter Wee PM, Niessen H, et al. Amadori albumin and advanced glycation end-product formation in peritoneal dialysis using icodex-trin. Pent Dial Int. 2001;21:43-51.
2. Cooker LA, Choo CG, Luneburg P, et al. Effect of icodextrin peritoneal dialysis solution on cell proliferation in vitro. Adv Perit Dial. 1999; 15:17-20.
3. Cooker LA, Luneburg P, Faict D, et al. Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int. 1997; 17: 373-378.
4. Park MS, Kim JK, Holmes C, et al. Effects of bicartoonate/lactate solution on peritoneal advanced glycosylation end-product accumulation. Perit Dial Int. 2000; 20 (Suppl 5): S33-S38.
5. Fusshoeller A, Plail M, Grabensee B, et al. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant. 2004; 19:2101-2106.
6. Bajo MA, del Peso G, Castro MA, et al. Effect of amino acid PD solutions on human mesothelial cell proliferation ex vivo. Abstr. Perit Dial Int. 2002; 22 (Suppl 1): S34.
7. Cappelli G, Bandiani G, Cancarini GC, et al. Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: prospective cross-over study with a three-compartment bag. Adv Perit Dial. 1999; 15:238-242.
8. Witowski J, Korybalska K, Ksiazek K, et al. Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. Nephrol Dial Transplant. 2004; 19:917-924.
9. Chan TM, Leung JK, Sun Y, et al. Different effects of amino acid-based and glucose-based dialysate from peritoneal dialysis patients on mesothelial cell ultrastructure and function. Nephrol Dial Transplant. 2003; 18: 1086-1094.
10. Zareie M, van Lambalgen AA, ter Wee PM, et al. Better preservation of the peritoneum in rats exposed to amino acid-based peritoneal dialysis fluid. Perit Dial Int. 2005; 25: 58-67.
11. Thomas S, Schenk U, Fischer FP, et al. In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis. 1997; 29: 246-253.
12. Topley N. In vitro biocompatibility of bicarbonate-based peritoneal dialysis solutions. Perit Dial Int. 1997; 17: 42-47.
13. Brulez HF, Dekker HA, Oe PL, et al. Biocompatibility of a 1.1% amino acid-containing peritoneal dialysis fluid compared to a 2.27% glucose-based peritoneal dialysis fluid. Nephron. 1996; 74:26-32.
14. Xing Z, Gauldie J, Cox G, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998; 101:311-320.
15. Topley N, Kaur D, Petersen MM, et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int. 1996; 49:1447-1456.
16. Riegel W, Ulrich C, Friedrichsohn C, et al. Liver cell reactive components in peritoneal dialysis fluids. Miner Electrolyte Metab. 1999; 25: 373-379.
17. Bender TO, Witowski J, Ksia̧zek K, Jörres A. Comparison of icodex-trin-and glucose-based peritoneal dialysis fluids in their acute and chronic effects on human peritoneal mesothelial cells. Int J Artif Organs. 2007; 30:1075-1082.
18. Gotloib L, Wajsbrot V, Shostak A. Osmotic agents hamper mesothelial repopulation as seen in the doughnut in vivo model. Perit Dial Int. 2005; 25 (Suppl 3): S26-S30.
19. Davies SJ, Brown EA, Frandsen NE, et al. EAPOS Group. Longitudinal membrane function in functionally amine patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int. 2005; 67:1609-1615.
20. Grzegorzewska AE, Antczak-Jȩdrzejczak D, Leander M. Results of peritoneal equilibration test during treatment with polyglucose dialysis solution. Peril Dial Int. 2002; 22: 357-364.
21. Posthuma N, Verbrugh HA, Donker AJM, et al. Peritoneal kinetics and mesothelial markers in CCPD using icodextrein for daytime dwell for two years. Perit Dial Int. 2000; 20:174-180.
22. Posthuma N, ter Wee PM, Donker AJ, et al. Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int. 2000; 20 (Suppl 2): S106-S113.
23. Martikainen TA, Teppo AM, Gronhagen-Riska C, et al. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int. 2005; 25: 453-460.
24. Li FK, Chan LY, Woo JC, et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis. 2003; 42: 1731-1783.
25. Rippe B, Simonsen 0, Heimbürger O, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int. 2001; 59: 348-357.
26. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int. 2000; 20: 516-523.
27. Otte K, Gonzalez MT, Bajo MA, et al. Clinical experience with a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dialysis solution. Perit Dial Int. 2003; 23:138-145.
28. Theodoridis M, Passadakis R Kriki R et al. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability. Ren Fail. 2008; 30:161-167.
29. Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products-a 1-year randomized control trial. Nephrol Dial Transplant. 2007; 22: 552-559.
30. Ha H, Cha MK, Choi HN, et al. Effects of peritoneal dialysis solutions on the secretion of growth factors and extracellular matrix proteins by human peritoneal mesothelial cells. Perit Dial Int. 2002; 22:171-177.
31. Tjiong HL, Zijlstra FJ, Rietveld T, et al. Peritoneal protein losses and cytokine generation in automated peritoneal dialysis with combined amino acids and glucose solutions. Mediators Inflamm. 2007; 2007: 97272.
32. Cooker LA, Luneburg R Holmes CJ, et al, on the behalf of the Bicar bonate/Lactate Study Group, lntedeukin-6 levels decrease in effluent from patients dialysed with bicarbonate/lactate-based peritoneal dialysis solu tion. Perit Dial Int. 2001; 21 (Suppl 3): S102-S107.
33. Povlsen JV, Ivarsen P, Jergensen KA, et al. Exposure to the peptidogly can contaminant in icodextrin may cause sensitization of the patient main tained on peritoneal dialysis. Perit Dial Int. 2003; 23: 509-510.
34. Seow YY, lies-Smith H, Hirst H, et al. Icodextrin-associated peritonitis among CAPD patients. Nephrol Dial Transplant. 2003; 18:1951-1952.
35. Donovan KL. Inflammation and peritoneal dialysis fluids. Perit Dial Int 2007, 27: 98-99.
36. Montenegro J, Saracho R, Gallardo I, et al. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis Nephrol Dial Transplant. 2007; 22:1703-1708.
37. Ahmad S, Sehmi JS, Ahmad-Zakhi KH, et al. Impact of new dialysis solutions on peritonitis rates. Kidney Int Suppl. 2006; 103: S63-S66.
38. Lee HY, Park HC, Seo BJ, et al. Superior patient survival for contim ous ambulatory peritoneal dialysis patients treated with a peritoneal dia ysis fluid with neutral pH and low glucose degradation product concentn tion (Balance). Perit Dial Int. 2005; 25: 248-255.
39. Gokal R, Mistry CD, Peers EM. Peritonitis occurrence in a multi-center study of icodextrin and glucose in CAPD. MIDAS Study Group. Mul-ticenter Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int. 1995; 15: 226-230.
40. Taylor GS, Patel V, Spencer S, et al. Long-term use of 1.1 % amino acid dialysis solution in hypoalbuminemic continuous ambulatory peritoneal dialysis patients. Clin Nephrol. 2002; 58: 445-450.
41. Wilkie ME, Plant MJ, Edwards L, et al. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int. 1997; 17: 84-87.
42. Mistry CD, Gokal R, Peers E. A randomized mufticenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int. 1994; 46:496-503.
43. le Poole CY, Welten AG, Weijmer MC, et al. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int. 2005; 25 (Suppl 3): S64-S68.
44. Brunkhorst R, Fromm S, Wrenger E, et al. Automated peritoneal dialysis with 'on-line'-prepared bicarbonate-buffered dialysate: technique and first clinical experiences. Nephrol Dial Transplant. 1998; 13:3189-3192.
45. Carrasco AM, Rubio MA, Sanchez Tommero JA, et al. Acidosis correction with a new 25 mmol/l bicarbonate/15 mmol/l lactate peritoneal dialysis solution. Perit Dial Int. 2001; 21: 546-553.
46. Guerrero A, Montes R, Martin-Herrera C, et al. [Clinical experience with icodextrin. Multicenter study]. Nefrologfa. 2001; 21: 574-580. Spanish.
47. Grzegorzewska AE, Mariak I, Dobrowolska-Zachwieja A, et al. Effects of amino acid dialysis solution on the nutrition of continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1999; 19:462-470.
48. Feriani M, Carobi C, La Greca G, et al. Clinical experience with a 39 mmol/l bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int. 1997; 17:17-21.
49. Plum J, Erren C, Fieseler C, et al. An amino acid-based peritoneal dialysis fluid buffered with bicarbonate versus glucose/bicarbonate and glu-cose/lactate solutions: an intraindividual randomised study. Perit Dial Int. 1999; 19: 418-428.